| 27.88 0.32 (1.16%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.96 | 1-year : | 42.25 |
| Resists | First : | 31.64 | Second : | 36.18 |
| Pivot price | 27.26  |
|||
| Supports | First : | 24.3 | Second : | 20.22 |
| MAs | MA(5) : | 27.55  |
MA(20) : | 28.27 |
| MA(100) : | 26.65 |
MA(250) : | 22.52 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 50.7 |
D(3) : | 44 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 36.43 | Low : | 13.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BEAM ] has closed below upper band by 34.5%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.93 - 28.04 | 28.04 - 28.12 |
| Low: | 26.48 - 26.6 | 26.6 - 26.71 |
| Close: | 27.68 - 27.89 | 27.89 - 28.05 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Wed, 18 Feb 2026
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory - Finviz
Wed, 18 Feb 2026
Readystate Asset Management LP Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Wed, 18 Feb 2026
13 Hot Stocks to Buy with the Highest Upside Potential - Insider Monkey
Tue, 17 Feb 2026
Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat
Mon, 16 Feb 2026
Here is Why Beam Therapeutics (BEAM) Appears so Attractive - Yahoo Finance
Sun, 15 Feb 2026
Why Beam Therapeutics (BEAM) Is Up 5.3% After New Gene-Editing IP Deal And FDA Fast Track - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 8.742e+007 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 19,790 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.4422e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 307.6 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 5.57e+007 % |
| Gross Profit (p.s.) | -15.46 |
| Sales Per Share | -22.8 |
| EBITDA (p.s.) | -1.72024e+008 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -338 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.23 |
| Price to Cash Flow | 5.88 |
| Dividend | 0 |
| Forward Dividend | 2.004e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|